AST 487
Based on 5 publication(s) in Google Scholar
AST 487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.90%
- CAS No.: 630124-46-8
- Formule: C26H30F3N7O2
- Masse moléculaire:529.56
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Cancer Compound Library
HY-L025
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Endocrinology Compound Library
HY-L047
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cytokine Inhibitors Library
HY-L161
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) AST 487
More
Customer Validation & Images
-
WB
Voir tous les produits spécifiques à Isoform VEGFR
More
Activité biologique
IC50: 880 nM (RET), 170 nM (KDR), 790 nM (Flt-4), 500 nM (c-Kit), 520 nM (Flt-3), 20 nM (Abl)[1]
A number of other kinases are also similarly inhibited by AST 487 (NVP-AST487) in the in vitro kinase assays, including KDR (IC50=170 nM), Flt-4 (IC50=790 nM), Flt-3 (IC50=520 nM), c-Kit (IC50=500 nM), and c-Abl (IC50=20 nM). AST 487 potently inhibits the growth of human thyroid cancer cell lines with activating mutations of RET but not of lines without RET mutations. Both GDNF/GFRα1 and persephin-induced calcitonin mRNA are markedly inhibited by coincubation with 100 nM of AST 487 in MTC-M cells[1]. AST 487 is a novel, mutant FLT3 inhibitor. AST 487 is tested in biochemical assays for inhibition of Flt-3 kinase activity. The Ki is determined to be 0.12 μM. Besides Flt-3, NVP-AST487 inhibits RET, KDR, c-Kit, and c-Abl kinase with IC50 values below 1 μM. Treatment of FLT3-ITD-Ba/F3 cells and D835Y-Ba/F3 cells with AST 487 potently inhibits cellular proliferation (IC50<5 nM). AST 487 treatment of FLT3-ITD-Ba/F3 cells with 0.01 μM AST 487 results in complete cell killing compare with approximately 50% killing of AML patient samples at the same concentration[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 630124-46-8
-
Appearance Solid
-
Masse moléculaire 529.56
-
Formule C26H30F3N7O2
-
Color White to off-white
-
SMILES
O=C(NC1=CC=C(OC2=NC=NC(NC)=C2)C=C1)NC3=CC=C(CN4CCN(CC)CC4)C(C(F)(F)F)=C3
-
Synonyms
NVP-AST 487
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Cell Res
Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington's disease models. [Abstract]2017 Dec;27(12):1441-1465. PMID: 29151587
AST 487 purchased from MedChemExpress. Usage Cited in: Cell Res. 2017 Dec;27(12):1441-1465. [Abstract]
AST487 effectively lowers mHTT levels, and this effect is mitigated by knocking down HIPK3, confirming that AST487 reduces mHTT levels via inhibiting HIPK3.
-
ACS Chem Biol
A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family. [Abstract]2017 May 19;12(5):1245-1256. PMID: 28263556 -
PLoS One
A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]2024 Nov 1;19(11):e0308647. PMID: 39485774 -
Protein Expr Purif
Refolding and purification of cGMP-grade recombinant human neurturin from Escherichia coli inclusion bodies. [Abstract]2020 Apr;168:105552. PMID: 31866372 -
Solvant et solubilité
DMSO : ≥ 100 mg/mL (188.84 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.72 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.72 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Glutathione S-transferase (GST)-fused kinase domains are expressed in baculovirus and purified over glutathione-sepharose. Kinase activity is tested by measuring the phosphorylation of a synthetic substrate [poly(Glu, Tyr)], by purified GST-fusion kinase domains of the respective protein kinase in the presence of radiolabeled ATP; the ATP concentrations used are optimized within the Km range for the individual kinases. Briefly, each kinase is incubated under optimized buffer conditions in 20 mM of Tris-HCl (pH 7.5), 1 to 3 mM of MnCl2, 3 to 10 mM of MgCl2, 10 μM of Na3VO4, 1 mM of DTT, 0.2 μCi [33P]ATP, 1 to 8 μM of ATP, 3 to 8 μg/mL of poly(Glu/Tyr, 4:1), and 1% DMSO in a total volume of 30 μL in the presence or absence of NVP-AST487 for 10 min at ambient temperature. Reactions are terminated by adding 10 μL of 250 mM EDTA, and the reaction mixture is transferred onto an Immobilon polyvinylidene difluoride membrane. Filters are washed (0.5% H3PO4), soaked in ethanol, dried and counted in a liquid scintillation counter. IC50s for AST 487 are calculated by linear regression analysis of the percentage inhibition[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
The trypan blue exclusion assay is used to determine proliferation of cells cultured in the presence and absence of NVP-AST 487. Cell viability is reported as percentage of control (untreated) cells, and data are presented as the average of 2 independent experiments, except where indicated. Error bars represent the standard error of the mean for each data point. Apoptosis of drug-treated cells is measured using the Annexin-V-Fluos Staining Kit. Cell-cycle analysis is performed[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[1]
Female athymic nude mice are kept under optimized hygienic conditions (maximum of 10 mice per Makrolon type III cage) with free access to food and water. Tumors are established by s.c. injection of 1×106 and 5×106 of NIH3T3-RETC634W and TT cells, respectively, in 100 μL of HBSS per mouse. Treatable tumors, i.e., mean tumor volume of 100 mm3, developed within 10 days of NIH3T3-RETC634W cell injection, and within 20 days of TT cell injection. NVP-AST487 is given p.o., once daily by gavage. The compound is formulated by dissolving the appropriate amount of powder in N-methylpyrrolidone/PEG300 (1:10 v/v). The mice are randomized into four treatment groups of eight mice each. The first three groups received daily oral administrations of NVP-AST487 at 50, 30, and 10 mg/kg, respectively, for 3 weeks. The fourth group received treatment with vehicle. Tumor growth and body weights are monitored twice weekly. Tumor volumes are determined according to the formula: length×diameter2×π/6. Tumors are collected and frozen in liquid nitrogen at the end of the efficacy study, 6 h after the last administration.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Akeno-Stuart N, et al. The RET Kinase Inhibitor NVP-AST487 Blocks Growth and Calcitonin Gene Expression through Distinct Mechanisms in Medullary Thyroid Cancer Cells. Cancer Res. 2007 Jul 15;67(14):6956-64. [Content Brief]
[2]. Weisberg E, et al. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood. 2008 Dec 15;112(13):5161-70. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8884 mL | 9.4418 mL | 18.8836 mL | 47.2090 mL |
| 5 mM | 0.3777 mL | 1.8884 mL | 3.7767 mL | 9.4418 mL | |
| 10 mM | 0.1888 mL | 0.9442 mL | 1.8884 mL | 4.7209 mL | |
| 15 mM | 0.1259 mL | 0.6295 mL | 1.2589 mL | 3.1473 mL | |
| 20 mM | 0.0944 mL | 0.4721 mL | 0.9442 mL | 2.3605 mL | |
| 25 mM | 0.0755 mL | 0.3777 mL | 0.7553 mL | 1.8884 mL | |
| 30 mM | 0.0629 mL | 0.3147 mL | 0.6295 mL | 1.5736 mL | |
| 40 mM | 0.0472 mL | 0.2360 mL | 0.4721 mL | 1.1802 mL | |
| 50 mM | 0.0378 mL | 0.1888 mL | 0.3777 mL | 0.9442 mL | |
| 60 mM | 0.0315 mL | 0.1574 mL | 0.3147 mL | 0.7868 mL | |
| 80 mM | 0.0236 mL | 0.1180 mL | 0.2360 mL | 0.5901 mL | |
| 100 mM | 0.0189 mL | 0.0944 mL | 0.1888 mL | 0.4721 mL |
Powered by Bioz